The stock of Farmland Partners Inc (FPI) has seen a 3.77% increase in the past week, with a 12.22% gain in the past month, and a 23.13% flourish in the past quarter. The volatility ratio for the week is 1.98%, and the volatility levels for the past 30 days are at 2.44% for FPI. The simple moving average for the last 20 days is 4.85% for FPI stock, with a simple moving average of 14.42% for the last 200 days.
Is It Worth Investing in Farmland Partners Inc (NYSE: FPI) Right Now?
The price-to-earnings ratio for Farmland Partners Inc (NYSE: FPI) is above average at 54.12x. The 36-month beta value for FPI is also noteworthy at 0.71. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 3 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for FPI is 43.51M, and at present, short sellers hold a 7.84% of that float. The average trading volume of FPI on November 21, 2024 was 315.08K shares.
FPI) stock’s latest price update
The stock price of Farmland Partners Inc (NYSE: FPI) has surged by 1.01 when compared to previous closing price of 12.41, but the company has seen a 3.77% gain in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-11 that Patient Enrolled at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital Aethlon’s Trial is a Safety, Feasibility, and Dose Finding Study of the Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies SAN DIEGO, Nov. 11, 2024 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier Study). The patient was enrolled on October 29, 2024, by Prof.
Analysts’ Opinion of FPI
Many brokerage firms have already submitted their reports for FPI stocks, with B. Riley Securities repeating the rating for FPI by listing it as a “Neutral.” The predicted price for FPI in the upcoming period, according to B. Riley Securities is $12.50 based on the research report published on December 13, 2023 of the previous year 2023.
ROTH Capital gave a rating of “Buy” to FPI, setting the target price at $16 in the report published on June 21st of the previous year.
FPI Trading at 12.02% from the 50-Day Moving Average
After a stumble in the market that brought FPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.39% of loss for the given period.
Volatility was left at 2.44%, however, over the last 30 days, the volatility rate increased by 1.98%, as shares surge +11.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +19.88% upper at present.
During the last 5 trading sessions, FPI rose by +3.31%, which changed the moving average for the period of 200-days by +13.76% in comparison to the 20-day moving average, which settled at $11.95. In addition, Farmland Partners Inc saw 0.44% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FPI starting from Good John A, who purchase 24,000 shares at the price of $10.15 back on Aug 07 ’24. After this action, Good John A now owns 86,465 shares of Farmland Partners Inc, valued at $243,574 using the latest closing price.
Fabbri Luca, the President and CEO of Farmland Partners Inc, purchase 1,000 shares at $10.00 during a trade that took place back on Aug 05 ’24, which means that Fabbri Luca is holding 321,344 shares at $10,000 based on the most recent closing price.
Stock Fundamentals for FPI
Current profitability levels for the company are sitting at:
- 0.36 for the present operating margin
- 0.68 for the gross margin
The net margin for Farmland Partners Inc stands at 0.32. The total capital return value is set at 0.02. Equity return is now at value 3.58, with 1.75 for asset returns.
Currently, EBITDA for the company is 60.9 million with net debt to EBITDA at -0.23. When we switch over and look at the enterprise to sales, we see a ratio of 10.21. The receivables turnover for the company is 4.77for trailing twelve months and the total asset turnover is 0.06.
Conclusion
In summary, Farmland Partners Inc (FPI) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
